biostudies-literaturevan Dijk ADNCINIH COGJunior Scientific Masterclass (Groningen, The Netherlands)NCI NIH HHS1448https://www.ebi.ac.uk/biostudies/studies/S-EPMC11048007biostudies-literatureUnknown16(8)The addition of the proteasome inhibitor bortezomib to standard chemotherapy did not improve survival in pediatric acute myeloid leukemia (AML) when all patients were analyzed as a group in the Children's Oncology Group phase 3 trial AAML1031 (NCT01371981). Proteasome inhibition influences the chromatin landscape and proteostasis, and we hypothesized that baseline proteomic analysis of histone- and chromatin-modifying enzymes (HMEs) would identify AML subgroups that benefitted from bortezomib addition. A proteomic profile of 483 patients treated with AAML1031 chemotherapy was generated using a reverse-phase protein array. A relatively high expression of 16 HME was associated with lower EFS and higher 3-year relapse risk after AML standard treatment compared to low expressions (52% vs. 29%,CancersChromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.PMC11048007U10 CA180886U10 CA98543R01-CA164024U24 CA196173U10 CA180899U10 CA98413van Dijk ADLeonti ARMeshinchi SHubner SEde Bont ESJMGo RLGerbing RBQiu YKornblau SMGamis ASHorton TMAplenc RHoff FWAlonzo TARuvolo VRKolb EAfalseChromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.The addition of the proteasome inhibitor bortezomib to standard chemotherapy did not improve survival in pediatric acute myeloid leukemia (AML) when all patients were analyzed as a group in the Children's Oncology Group phase 3 trial AAML1031 (NCT01371981). Proteasome inhibition influences the chromatin landscape and proteostasis, and we hypothesized that baseline proteomic analysis of histone- and chromatin-modifying enzymes (HMEs) would identify AML subgroups that benefitted from bortezomib addition. A proteomic profile of 483 patients treated with AAML1031 chemotherapy was generated using a reverse-phase protein array. A relatively high expression of 16 HME was associated with lower EFS and higher 3-year relapse risk after AML standard treatment compared to low expressions (52% vs. 29%,2024-01-01T00:00:00Z2024 Apr2026-04-08T19:52:15.017Z2026-04-08T14:32:43.348ZS-EPMC110480073867253110.3390/cancers16081448